Ilya Y. Shadrin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ilya Y. Shadrin has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Nenad Bursac
Duke University
6 shared publications Daniel J. Friedman
Duke University Hospital, Durham, North Carolina
3 shared publicationsAlbert Y. Sun
Department of Medicine Division of Cardiology Duke University Hospital Durham North Carolina USA
2 shared publications- Atta Behfar
Mayo Clinic
2 shared publications Donald D. Hegland
Department of Medicine Division of Cardiology Duke University Hospital Durham North Carolina USA
2 shared publicationsSana M. Al‐Khatib
Department of Medicine Division of Cardiology Duke University Hospital Durham North Carolina USA
2 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (10) , 1950-1962
Relationship between site procedural volumes and outcomes of left bundle branch area pacing using stylet-driven leads from the INSIGHT-LBBA Registry
- 20 July 2026
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (10) , 1950-1962
Open AccessRelationship between site procedural volumes and outcomes of left bundle branch area pacing using stylet-driven leads from the INSIGHT-LBBA Registry
- 25 February 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 49 (8) , 1133-1142
Sex‐Based Differences in Left Bundle Branch Capture During Left Bundle Branch Area Pacing
Objective: To identify sex‐based differences in meeting left bundle branch (LBB) capture criteria on postimplant ECGs. Background: Despite differences in QRS duration (QRSd) between males and females, no sex‐based criteria have been established for defining LBB capture during LBB area pacing (LBBAP). Methods: Patients aged >18 y.o. with a pacing indication and dual‐chamber LBBAP pacemaker implantation from 2020 to 2023 were studied. Baseline and postoperative day 1 (POD1) ECGs were assessed for electrical dyssynchrony (QRS‐area, sum‐absolute integral of QRS‐T (SAI QRS‐T)), with LBB capture defined based on R‐wave peak times (RWPT) per the EHRA 2023 Consensus algorithm. Results: The cohort included 222 patients (143 males/79 females, age 74.5±1.1 years, LVEF 53.7±0.4%). Baseline QRSd was significantly shorter among females than males (median 122 ms [90,134] vs 126 ms [102,146]; p = 0.018). LBB capture criteria were met in 83 (58.0%) male and 56 (70.9%) female patients ( p = 0.058). Baseline and POD1 dyssynchrony were similar between sexes. However, RWPTs measured in leads V 6 /I/aVL were ∼7 ms shorter in females than males (V 6 ‐RWPT: 66.3 ± 1.6 ms vs. 73.7 ± 1.4 ms, p = 0.0008). Adjusting V 6 ‐RWPT up by 7 ms in females resulted in 7/56 patients (12.5%) no longer meeting LBB capture criteria. Significant differences were eliminated when normalizing RWPTs to size parameters (LV size, height, body surface area (BSA)), with no significant correlation between V 6 ‐RWPT and size. Conclusions: Females with LBB capture exhibit shorter V 6 ‐RWPTs despite similar measures of electrical dyssynchrony. This difference disappears when normalizing for the smaller size of female hearts. Additional studies are warranted to establish sex‐specific LBB capture criteria. Graphical Despite innate differences in QRS duration between males and females, no recommendations have been established to assess for left bundle branch (LBB) capture across different sexes in patients undergoing LBB area pacing (LBBAP). To this end, we performed a retrospective study analyzing postimplant ECGs from 222 patients (143 males/79 females). R‐wave peak times (RWPTs), traditionally used to identify LBB capture, were noted to be ∼7 ms shorter in females vs. males, with the differences resolved when accounting for smaller size of female hearts despite no correlation between RWPT and body/heart size. These results argue towards establishing sex‐based cutoffs for LBB capture.
- 25 February 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 49 (8) , 1133-1142
Sex‐Based Differences in Left Bundle Branch Capture During Left Bundle Branch Area Pacing
Objective: To identify sex‐based differences in meeting left bundle branch (LBB) capture criteria on postimplant ECGs. Background: Despite differences in QRS duration (QRSd) between males and females, no sex‐based criteria have been established for defining LBB capture during LBB area pacing (LBBAP). Methods: Patients aged >18 y.o. with a pacing indication and dual‐chamber LBBAP pacemaker implantation from 2020 to 2023 were studied. Baseline and postoperative day 1 (POD1) ECGs were assessed for electrical dyssynchrony (QRS‐area, sum‐absolute integral of QRS‐T (SAI QRS‐T)), with LBB capture defined based on R‐wave peak times (RWPT) per the EHRA 2023 Consensus algorithm. Results: The cohort included 222 patients (143 males/79 females, age 74.5±1.1 years, LVEF 53.7±0.4%). Baseline QRSd was significantly shorter among females than males (median 122 ms [90,134] vs 126 ms [102,146]; p = 0.018). LBB capture criteria were met in 83 (58.0%) male and 56 (70.9%) female patients ( p = 0.058). Baseline and POD1 dyssynchrony were similar between sexes. However, RWPTs measured in leads V 6 /I/aVL were ∼7 ms shorter in females than males (V 6 ‐RWPT: 66.3 ± 1.6 ms vs. 73.7 ± 1.4 ms, p = 0.0008). Adjusting V 6 ‐RWPT up by 7 ms in females resulted in 7/56 patients (12.5%) no longer meeting LBB capture criteria. Significant differences were eliminated when normalizing RWPTs to size parameters (LV size, height, body surface area (BSA)), with no significant correlation between V 6 ‐RWPT and size. Conclusions: Females with LBB capture exhibit shorter V 6 ‐RWPTs despite similar measures of electrical dyssynchrony. This difference disappears when normalizing for the smaller size of female hearts. Additional studies are warranted to establish sex‐specific LBB capture criteria. Graphical Despite innate differences in QRS duration between males and females, no recommendations have been established to assess for left bundle branch (LBB) capture across different sexes in patients undergoing LBB area pacing (LBBAP). To this end, we performed a retrospective study analyzing postimplant ECGs from 222 patients (143 males/79 females). R‐wave peak times (RWPTs), traditionally used to identify LBB capture, were noted to be ∼7 ms shorter in females vs. males, with the differences resolved when accounting for smaller size of female hearts despite no correlation between RWPT and body/heart size. These results argue towards establishing sex‐based cutoffs for LBB capture.
- 4 June 2025
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 48 (7) , 765-775
Characterization of Septal Scar After Left Bundle Branch Area Pacemaker Implantation
Background: Left bundle branch area pacing (LBBAP) is increasingly used in patients with a ventricular pacing indication but necessitates precise septal localization. The resulting effects of intraoperative lead repositioning on septal fibrosis remain unknown. Objective: To assess the safety of cardiac magnetic resonance imaging (cMRI) in patients with LBBAP pacemakers and evaluate the septal myocardium via cMRI following LBBAP implantation compared with standard RV endocardial pacing (RVP). Methods: Patients aged > 18 y.o. with bradycardia, LBBAP or RVP implant from 2021 to 2023, and at least one cMRI after implant were identified. LBBAP versus RVP was verified per established criteria. Delayed‐enhancement cMRI and native T1 relaxation times were used to characterize myocardial scar. Results: A total of 34 patients were identified—20 with LBBAP implants (9 with matched pre‐implant cMRI) and 14 with RVP implants (3 with matched pre‐implant cMRI)—with no evidence of ventricular septal defects post‐implant. LBBAP lead parameters were stable pre‐/post‐cMRI and out to 9 months. Comparing pre‐ versus post‐implant cMRIs (median 579 days apart), 1/9 patients following LBBAP showed a new scar on the RV inferoseptal side directly adjacent to the pacing lead on post‐implant cMRI, suggestive of potential implant‐related scarring with LBBAP. Conclusion: CMRI appears safe for patients with LBBAP pacemakers, with stable short‐ and long‐term device parameters. In patients with matched pre/post‐implant cMRIs, the new septal scar can be identified with LBBAP implantation, raising the possibility of lead‐related fibrosis. Larger studies are required to substantiate whether the single case of lead‐related fibrosis is an exception or occurs more frequently.
- 4 June 2025
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 48 (7) , 765-775
Characterization of Septal Scar After Left Bundle Branch Area Pacemaker Implantation
Background: Left bundle branch area pacing (LBBAP) is increasingly used in patients with a ventricular pacing indication but necessitates precise septal localization. The resulting effects of intraoperative lead repositioning on septal fibrosis remain unknown. Objective: To assess the safety of cardiac magnetic resonance imaging (cMRI) in patients with LBBAP pacemakers and evaluate the septal myocardium via cMRI following LBBAP implantation compared with standard RV endocardial pacing (RVP). Methods: Patients aged > 18 y.o. with bradycardia, LBBAP or RVP implant from 2021 to 2023, and at least one cMRI after implant were identified. LBBAP versus RVP was verified per established criteria. Delayed‐enhancement cMRI and native T1 relaxation times were used to characterize myocardial scar. Results: A total of 34 patients were identified—20 with LBBAP implants (9 with matched pre‐implant cMRI) and 14 with RVP implants (3 with matched pre‐implant cMRI)—with no evidence of ventricular septal defects post‐implant. LBBAP lead parameters were stable pre‐/post‐cMRI and out to 9 months. Comparing pre‐ versus post‐implant cMRIs (median 579 days apart), 1/9 patients following LBBAP showed a new scar on the RV inferoseptal side directly adjacent to the pacing lead on post‐implant cMRI, suggestive of potential implant‐related scarring with LBBAP. Conclusion: CMRI appears safe for patients with LBBAP pacemakers, with stable short‐ and long‐term device parameters. In patients with matched pre/post‐implant cMRIs, the new septal scar can be identified with LBBAP implantation, raising the possibility of lead‐related fibrosis. Larger studies are required to substantiate whether the single case of lead‐related fibrosis is an exception or occurs more frequently.
- 10 November 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 211, 61-73
In vitro vascularization improves in vivo functionality of human engineered cardiac tissues
- 10 November 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 211, 61-73
In vitro vascularization improves in vivo functionality of human engineered cardiac tissues
- Open Access
- 26 September 2024
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 11 (1) , 85-88
Incessant device-initiated wide complex tachycardia: What is the mechanism?
- 26 September 2024
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 11 (1) , 85-88
Open AccessIncessant device-initiated wide complex tachycardia: What is the mechanism?
- Open Access
- 28 November 2023
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 10 (2) , 158-161
Impact of flecainide on left bundle branch capture criteria
- 28 November 2023
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 10 (2) , 158-161
Open AccessImpact of flecainide on left bundle branch capture criteria
- Open Access
- 3 January 2023
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 98 (1) , 150-162
Left Internal Mammary Artery as an Endocrine Organ: Insights Into Graft Biology and Long-term Impact Following Coronary Artery Bypass Grafting
- 3 January 2023
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 98 (1) , 150-162
Open AccessLeft Internal Mammary Artery as an Endocrine Organ: Insights Into Graft Biology and Long-term Impact Following Coronary Artery Bypass Grafting
- 21 August 2020
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 67 (4) , e81-e85
Percutaneous Axillary Intra-aortic Balloon Pump Insertion Technique as Bridge to Advanced Heart Failure Therapy
In patients with advanced heart failure (HF), temporary mechanical circulator support (TMCS) is used to improve hemodynamics, via left ventricular unloading, and end-organ function as a bridge to definitive therapy. While listed for cardiac transplantation, use of TMCS may be prolonged, preventing adequate mobility. Here, we describe the technique for placement of a percutaneous axillary intra-aortic balloon pump (IABP) using single-site arterial access to facilitate ambulation and subsequent safe removal without surgery or a closure device. Retrospective review of the experience with this approach at a single institution between September 2017 and February 2020 documented feasibility and safety. Baseline demographics, hemodynamic data, and clinical outcomes were collected. Thirty-eight patients had a total of 56 IABPs placed. There were no significant access site or cerebrovascular complications. One fifth of IABPs (21.4%) had balloon failure or migration, requiring placement of a new device, though no patients had significant complications from balloon failure. The majority (81.6%) of patients in the cohort on axillary IABP support were ambulatory and ultimately received the intended therapy (63.2% transplant, 13.2% durable left ventricular assist device, 5.3% other cardiac surgery). Percutaneous, axillary IABP is feasible and associated with an acceptable complication rate as a bridge to definitive therapy.
- 21 August 2020
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 67 (4) , e81-e85
Percutaneous Axillary Intra-aortic Balloon Pump Insertion Technique as Bridge to Advanced Heart Failure Therapy
In patients with advanced heart failure (HF), temporary mechanical circulator support (TMCS) is used to improve hemodynamics, via left ventricular unloading, and end-organ function as a bridge to definitive therapy. While listed for cardiac transplantation, use of TMCS may be prolonged, preventing adequate mobility. Here, we describe the technique for placement of a percutaneous axillary intra-aortic balloon pump (IABP) using single-site arterial access to facilitate ambulation and subsequent safe removal without surgery or a closure device. Retrospective review of the experience with this approach at a single institution between September 2017 and February 2020 documented feasibility and safety. Baseline demographics, hemodynamic data, and clinical outcomes were collected. Thirty-eight patients had a total of 56 IABPs placed. There were no significant access site or cerebrovascular complications. One fifth of IABPs (21.4%) had balloon failure or migration, requiring placement of a new device, though no patients had significant complications from balloon failure. The majority (81.6%) of patients in the cohort on axillary IABP support were ambulatory and ultimately received the intended therapy (63.2% transplant, 13.2% durable left ventricular assist device, 5.3% other cardiac surgery). Percutaneous, axillary IABP is feasible and associated with an acceptable complication rate as a bridge to definitive therapy.
- 1 April 2020
- Published by Elsevier in The American Journal of Medicine
- Vol. 133 (4) , e149-e150
Pulmonary Hypertension and Pericardial Effusions—To Tap or Not to Tap
- 1 April 2020
- Published by Elsevier in The American Journal of Medicine
- Vol. 133 (4) , e149-e150
Pulmonary Hypertension and Pericardial Effusions—To Tap or Not to Tap
- Top Cited PapersOpen Access
- 28 November 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 1-15
Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues
Despite increased use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) for drug development and disease modeling studies, methods to generate large, functional heart tissues for human therapy are lacking. Here we present a “Cardiopatch” platform for 3D culture and maturation of hiPSC-CMs that after 5 weeks of differentiation show robust electromechanical coupling, consistent H-zones, I-bands, and evidence for T-tubules and M-bands. Cardiopatch maturation markers and functional output increase during culture, approaching values of adult myocardium. Cardiopatches can be scaled up to clinically relevant dimensions, while preserving spatially uniform properties with high conduction velocities and contractile stresses. Within window chambers in nude mice, cardiopatches undergo vascularization by host vessels and continue to fire Ca2+ transients. When implanted onto rat hearts, cardiopatches robustly engraft, maintain pre-implantation electrical function, and do not increase the incidence of arrhythmias. These studies provide enabling technology for future use of hiPSC-CM tissues in human heart repair.
- 28 November 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 1-15
Top Cited PapersOpen AccessCardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues
Despite increased use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) for drug development and disease modeling studies, methods to generate large, functional heart tissues for human therapy are lacking. Here we present a “Cardiopatch” platform for 3D culture and maturation of hiPSC-CMs that after 5 weeks of differentiation show robust electromechanical coupling, consistent H-zones, I-bands, and evidence for T-tubules and M-bands. Cardiopatch maturation markers and functional output increase during culture, approaching values of adult myocardium. Cardiopatches can be scaled up to clinically relevant dimensions, while preserving spatially uniform properties with high conduction velocities and contractile stresses. Within window chambers in nude mice, cardiopatches undergo vascularization by host vessels and continue to fire Ca2+ transients. When implanted onto rat hearts, cardiopatches robustly engraft, maintain pre-implantation electrical function, and do not increase the incidence of arrhythmias. These studies provide enabling technology for future use of hiPSC-CM tissues in human heart repair.